Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750575 | 1.00 | CASP1 (0.38) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL732868 | 0.99 | CASP1 (0.40) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL749987 | 0.99 | CASP1 (0.40) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL731144 | 0.97 | CASP1 (0.36) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL733185 | 0.96 | EPHX1 (0.38) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL749162 | 0.96 | EPHX1 (0.38) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL749178 | 0.95 | EPHX1 (0.37) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL1241766 | 0.95 | EPHX1 (0.37) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL731071 | 0.95 | EPHX1 (0.40) | CASP1ALDH1A1NPSR1HRH3EPHX1 | |
| SCHEMBL750012 | 0.95 | EPHX1 (0.40) | CASP1ALDH1A1NPSR1HRH3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377873-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20100298210-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | CASP1 179/4885ALDH1A1 1199/4885NPSR1 4083/4885 |
| US-20100298210-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | CASP1 156/4885ALDH1A1 1075/4885NPSR1 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.